Karuna Therapeutics Inc
Change company Symbol lookup
Select an option...
KRTX Karuna Therapeutics Inc
SNSE Sensei Biotherapeutics Inc
ALGS Aligos Therapeutics Inc
SRRA Sierra Oncology Inc
ATOS Atossa Therapeutics Inc
OSMT Osmotica Pharmaceuticals PLC
SAND Sandstorm Gold Ltd
GRVI Grove Inc
STON Stonemor Inc
TK Teekay Corp
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is developing a pipeline of therapeutic programs to address symptoms associated with schizophrenia and psychosis associated with Alzheimer’s disease (AD), as well as various forms of pain. KarXT is a combination of xanomeline and trospium. KarXT combines xanomeline, a muscarinic agonist, with trospium, a muscarinic antagonist, to stimulate muscarinic receptors in the CNS. It is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms.

Price
Delayed
$123.33
Day's Change
-1.28 (-1.03%)
Bid
--
Ask
--
B/A Size
--
Day's High
125.49
Day's Low
121.22
Volume
(Light)

Today's volume of 24,731 shares is on pace to be much lighter than KRTX's 10-day average volume of 191,081 shares.

24,731

Albemarle Corporation to Release Third-Quarter 2021 Earnings Results on Wednesday, Nov. 3, 2021

4:15 pm ET September 21, 2021 (PR Newswire) Print

Albemarle Corporation (NYSE: ALB), a leader in the global specialty chemicals industry, announced today that it will release its third-quarter 2021 earnings after the NYSE closes on Wednesday, Nov. 3, 2021.

https://mma.prnewswire.com/media/75024/albemarle_corporation_logo.jpg

The company will hold its conference call to discuss third-quarter 2021 results on Thursday, Nov. 4, at 9:00 a.m. ET. This call will be webcast and can be accessed through Albemarle Corporation's website at https://investors.albemarle.com/, via the webcast link below or by phone at the following number:

US Toll free:         +1 844 347 1034
International direct: +1 209 905 5910
Passcode:             6875708
Webcast:              Q3 Webcast Link

To avoid registration wait times, participants are encouraged to use the webcast link as the primary listening source. If a caller anticipates asking a question, please dial in 15 minutes before the start of the call to be placed in the queue early.

An online replay of this call will be available on Albemarle Corporation's website (for 12 months) and by phone at the following number (for 7 days):

US Toll free:         +1 855 859 2056
International direct: +1 404 537 3406
Passcode:             6875708

About Albemarle CorporationAlbemarle Corporation (NYSE: ALB) is a global specialty chemicals company with leading positions in lithium, bromine and refining catalysts. We think beyond business as usual to power the potential of companies in many of the world's largest and most critical industries, such as energy, electronics, and transportation. We actively pursue a sustainable approach to managing our diverse global footprint of world-class resources. In conjunction with our highly experienced and talented global teams, our deep-seated values, and our collaborative customer relationships, we create value-added and performance-based solutions that enable a safer and more sustainable future.

We regularly post information to www.albemarle.com, including notification of events, news, financial performance, investor presentations and webcasts, non-GAAP reconciliations, SEC filings and other information regarding our company, its businesses and the markets it serves.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding Albemarle Corporation's business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report on Form 10-K.

https://c212.net/c/img/favicon.png?sn=PH13988&sd=2021-09-21

View original content to download multimedia:https://www.prnewswire.com/news-releases/albemarle-corporation-to-release-third-quarter-2021-earnings-results-on-wednesday-nov-3-2021-301381898.html

SOURCE Albemarle Corporation

https://rt.prnewswire.com/rt.gif?NewsItemId=PH13988&Transmission_Id=202109211615PR_NEWS_USPR_____PH13988&DateId=20210921

comtex tracking

COMTEX_393756717/1005/2021-09-21T16:15:11

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.